Its own version of semaglutide earned margins of 70 to 80%; selling branded Wegovy earns 10 to 20%, which opened a hole in profit.
To fill it, Hims added eight health brand partners in one week, including Dexcom's glucose monitor, Flo Health and Natural Cycles.
Each partner adds a data stream to one subscriber record, aiming for a switching cost made of years of personal health history.
Abroad the old model still runs: Hims launched generic semaglutide in Canada at 149 Canadian dollars a month, against up to 400 for Ozempic.
The open question is retention: fewer than half of people starting branded Wegovy still take it after six months; can the new partnerships change that?